Amino Acids

, Volume 36, Issue 4, pp 685–691

A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease?

Review Article


Coeliac disease is an autoimmune-mediated disorder with both innate and adaptive immune components. The disease is triggered by dietary gluten, which provokes the development of a massive immune reaction leading to the destruction of the small-intestinal mucosal morphology and intestinal dysfunction. Besides the typical small-bowel symptoms extraintestinal manifestations may also arise in a subset of coeliac disease patients. In addition, gluten evokes the production of antibodies mainly targeting deamidated gluten peptides or transglutaminase 2. Although coeliac disease has traditionally been regarded as a T cell-mediated disorder, this review discusses the role of the gluten-induced disease-specific anti-transglutaminase 2-autoantibodies in the pathogenesis of the disease.


Coeliac disease Transglutaminase 2 Autoantibodies Pathogenesis 


  1. Aeschlimann D, Aeschlimann P, Strigun A, Woodroofe N, Hadjivassiliou M (2007) TG6-specific antibodies in sera from patients with celiac disease: implications for extraintestinal disease manifestations. In: Abstract book of ninth international conference on transglutaminases and protein cross linkingGoogle Scholar
  2. Akimov SS, Krylov D, Fleischman LF, Belkin AM (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148:825–838PubMedCrossRefGoogle Scholar
  3. Ankelo M, Kleimola V, Simell S, Simell O, Knip M, Jokisalo E, Tarkia M, Westerlund A, He Q, Viander M, Ilonen J, Hinkkanen AE (2007) Antibody responses to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease. Clin Exp Immunol 150:285–293PubMedGoogle Scholar
  4. Aoki-Ota M, Tsunoda K, Ota T, Iwasaki T, Koyasu S, Amagai M, Nishikawa T (2004) A mouse model of pemphigus vulgaris by adoptive transfer of naïve splenocytes from desmoglein 3 knockout mice. Brit J Dermatol 151:346–354CrossRefGoogle Scholar
  5. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M (2002) Analysis of tissue transglutaminase function in the migration of swiss 3T3 fibroblasts: The active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277:16567–16575PubMedCrossRefGoogle Scholar
  6. Barone MV, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D, Troncone R, Auricchio S, Esposito C (2007) Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology 132:1245–1253PubMedCrossRefGoogle Scholar
  7. Beissbarth T, Tye-Din JA, Smyth GK, Speed TP, Anderson RP (2005) A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Bioinformatics 21:29–37CrossRefGoogle Scholar
  8. Bister V, Kolho KL, Karikoski R, Westerholm-Ormio M, Savilahti E, Saarialho-Kere U (2005) Metalloelastase (MMP-12) is upregulated in the gut of pediatric patients with potential celiac disease and in type 1 diabetes. Scand J Gastroenterol 40:1413–1422PubMedCrossRefGoogle Scholar
  9. Boscolo S, Sarich A, Lorenzon A, Passoni M, Rui V, Stebel M, Sblattero D, Marzari R, Hadjivassiliou M, Tongiorgi E (2007) Gluten ataxia: passive transfer in a mouse model. Ann N Y Acad Sci 1107:319–328PubMedCrossRefGoogle Scholar
  10. Byrne G, Ryan F, Jackson J, Feighery C, Kelly J (2007) Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding. Gut 56:336–341PubMedCrossRefGoogle Scholar
  11. Cervio E, Volta U, Verri M, Boschi F, Pastoris O, Granito A, Barbara G, Parisi C, Felicani C, Tonini M, De Giorgio R (2007) Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro. Gastroenterology 133:195–206PubMedCrossRefGoogle Scholar
  12. Ciccocioppo R, Di Sabatino A, Bauer M, Della Riccia DN, Bizzini F, Biagi F, Cifone MG, Corazza GR, Schuppan D (2005) Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 85:397–407PubMedCrossRefGoogle Scholar
  13. Collin P, Pirttilä T, Nurmikko T, Somer H, Erilä T, Keyriläinen O (1991) Celiac disease, brain atrophy, and dementia. Neurology 41:372–375PubMedGoogle Scholar
  14. Collin P, Huhtala H, Virta L, Kekkonen L, Reunala T (2007) Diagnosis of celiac disease in clinical practice: physician’s alertness to the condition essential. J Clin Gastroenterol 41:152–156PubMedCrossRefGoogle Scholar
  15. Cooke WT, Holmes GKT (1984) Coeliac Disease. Churchill Livingstone, New YorkGoogle Scholar
  16. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3:797–801PubMedCrossRefGoogle Scholar
  17. Dieterich W, Trapp D, Esslinger B, Leidenberger M, Piper J, Hahn E, Schuppan D (2003) Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut 52:1562–1566PubMedCrossRefGoogle Scholar
  18. Dieterich W, Esslinger B, Trapp D, Hahn E, Huff T, Seilmeier W, Wieser H, Schuppan D (2006) Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut 55:478–484PubMedCrossRefGoogle Scholar
  19. Esposito C, Paparo F, Caputo I, Rossi M, Maglio M, Sblattero D, Not T, Porta R, Auricchio S, Marzari R, Troncone R (2002) Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut 51:177–181PubMedCrossRefGoogle Scholar
  20. Fesus L, Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27:534–539PubMedCrossRefGoogle Scholar
  21. Freeman HJ (2004) Adult celiac disease and the severe “flat” small bowel biopsy lesion. Dig Dis Sci 49:535–545PubMedCrossRefGoogle Scholar
  22. Gianfrani C, Auricchio S, Troncone R (2005) Adaptive and innate immune responses in celiac disease. Immunol Lett 99:141–145PubMedCrossRefGoogle Scholar
  23. Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ, Milford-Ward A (1996) Does cryptic gluten sensitivity play a part in neurological illness? Lancet 347:369–371PubMedCrossRefGoogle Scholar
  24. Hadjivassiliou M, Mäki M, Sanders DS, Williamson CA, Grünewald RA, Woodroofe NM, Korponay-Szabó IR (2006) Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 66:373–377PubMedCrossRefGoogle Scholar
  25. Halttunen T (2000) Biological functions of coeliac disease autoantibodies. Tampere University Press, TampereGoogle Scholar
  26. Halttunen T, Mäki M (1999) Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology 116:566–572PubMedCrossRefGoogle Scholar
  27. Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS (1999) Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 13:1787–1795PubMedGoogle Scholar
  28. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C (2002) Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 283:G996–G1003PubMedGoogle Scholar
  29. Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N, Caillat-Zucman S (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21:367–377PubMedCrossRefGoogle Scholar
  30. Jabri B, Sollid LM (2006) Mechanisms of disease: Immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 3:516–525PubMedCrossRefGoogle Scholar
  31. Jelinkova L, Tuckova L, Cinova J, Flegelova Z, Tlaskalova-Hogenova H (2004) Gliadin stimulates human monocytes to production of IL-8 and TNF-alpha through a mechanism involving NF-kappaB. FEBS Lett 571:81–85PubMedCrossRefGoogle Scholar
  32. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13:1442–1453PubMedCrossRefGoogle Scholar
  33. Juuti-Uusitalo K, Mäki M, Kainulainen H, Isola J, Kaukinen K (2007) Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol 150:294–305PubMedGoogle Scholar
  34. Kaukinen K, Peräaho M, Collin P, Partanen J, Woolley N, Kaartinen T, Nuutinen T, Halttunen T, Mäki M, Korponay-Szabo I (2005) Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. Scand J Gastroenterol 40:564–572PubMedCrossRefGoogle Scholar
  35. Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Mäki M (2007) Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol 42:1428–1433PubMedCrossRefGoogle Scholar
  36. Kiraly R, Vecsei Z, Demenyi T, Korponay-Szabo IR, Fesus L (2006) Coeliac autoantibodies can enhance transamidating and inhibit GTPase activity of tissue transglutaminase: Dependence on reaction environment and enzyme fitness. J Autoimmun 26:278–287PubMedCrossRefGoogle Scholar
  37. Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs L, Mäki M (2004) In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 53:641–648PubMedCrossRefGoogle Scholar
  38. Korponay-Szabo IR, Vecsei Z, Kiraly R, Dahlbom I, Chirdo F, Nemes E, Fesus L, Mäki M (2008) Deamidated gliadin peptides form epitopes that transglutaminase antibodies recognize. J Ped Gastroenterol Nutr 46:253–261CrossRefGoogle Scholar
  39. Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, Thorsby E, Sollid LM (1993) Gliadin-specific, HLA-DQ(alpha 1*0501, beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 178:187–196PubMedCrossRefGoogle Scholar
  40. Luostarinen L, Pirttilä T, Collin P (1999) Coeliac disease presenting with neurological disorders. Eur Neurol 42:132–135PubMedCrossRefGoogle Scholar
  41. Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M (2000) Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119:996–1006PubMedCrossRefGoogle Scholar
  42. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio S, Picard J, Osman M, Quaratino S, Londei M (2003) Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362:30–37PubMedCrossRefGoogle Scholar
  43. Marzari R, Sblattero D, Florian F, Tongiorgi E, Not T, Tommasini A, Ventura A, Bradbury A (2001) Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease. J Immunol 166:4170–4176PubMedGoogle Scholar
  44. Molberg O, Kett K, Scott H, Thorsby E, Sollid LM, Lundin KE (1997) Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 46:103–109CrossRefGoogle Scholar
  45. Molberg O, Mcadam SN, Korner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Norén O, Roepstorff P, Lundin KE, Sjöström H, Sollid LM (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4:713–717PubMedCrossRefGoogle Scholar
  46. Mustalahti K, Collin P, Sievanen H, Salmi J, Mäki M (1999) Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 354:744–745PubMedCrossRefGoogle Scholar
  47. Myrsky E, Kaukinen K, Syrjänen M, Korponay-Szabo IR, Mäki M, Lindfors K (2008) Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin Exp Immunol 152:111–119PubMedGoogle Scholar
  48. Mäki M (1994) Autoantibodies as markers of autoimmunity in coeliac disease pathogenesis. In: Feighery C, O’Farrelly C (eds) Gastrointestinal immunology and gluten-sensitive disease. Proceedings of the Sixth International Symposium on coeliac disease held at Trinity College, Dublin in July 1992. Oak Tree Press, DublinGoogle Scholar
  49. Niveloni S, Sugai E, Cabanne A, Vazquez H, Argonz J, Smecuol E, Moreno ML, Nachman F, Mazure R, Kogan Z, Gomez JC, Mauriño E, Bai JC (2007) Antibodies against synthetic deamidated gliadin peptides as predictors of celiac disease: Prospective assessment in an adult population with a high pretest probability of disease. Clin Chem 53:2186–2192PubMedCrossRefGoogle Scholar
  50. Pinkas DM, Strop P, Brunger AT, Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5:e327PubMedCrossRefGoogle Scholar
  51. Saalman R, Wold AE, Dahlgren UI, Fallstrom SP, Hanson LA, Ahlstedt S (1998) Antibody-dependent cell-mediated cytotoxicity to gliadin-coated cells with sera from children with coeliac disease. Scand J Immunol 47:37–42PubMedCrossRefGoogle Scholar
  52. Salmi TT, Collin P, Korponay-Szabo IR, Laurila K, Partanen J, Huhtala H, Király R, Lorand L, Reunala T, Mäki M, Kaukinen K (2006) Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. Gut 55:1746–1753PubMedCrossRefGoogle Scholar
  53. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N (2002) Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 195:747–757PubMedCrossRefGoogle Scholar
  54. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C (2002) Structural basis for gluten intolerance in celiac sprue. Science 297:2275–2279PubMedCrossRefGoogle Scholar
  55. Shaoul R, Lerner A (2007) Associated autoantibodies in celiac disease. Autoimmun Rev 6:559–565PubMedCrossRefGoogle Scholar
  56. Skovbjerg H, Koch C, Anthonsen D, Sjöström H (2004) Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease. Biochim Biophys Acta 1690:220–230PubMedGoogle Scholar
  57. Smecuol E, Bai JC, Vazquez H, Kogan Z, Cabanne A, Niveloni S, Pedreira S, Boerr L, Mauriño E, Meddings JB (1997) Gastrointestinal permeability in celiac disease. Gastroenterology 112:1129–1136PubMedCrossRefGoogle Scholar
  58. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2:647–655PubMedCrossRefGoogle Scholar
  59. Sollid LM, Molberg O, McAdam S, Lundin KE (1997) Autoantibodies in coeliac disease: tissue transglutaminase-guilt by association? Gut 41:851–852PubMedCrossRefGoogle Scholar
  60. Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D (1998) Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 164:157–168PubMedCrossRefGoogle Scholar
  61. Visakorpi JK, Mäki M (1994) Changing clinical features of coeliac disease. Acta Paediatr Suppl 83:10–13PubMedCrossRefGoogle Scholar
  62. Volta U, De Giorgio R, Petrolini N, Stangbellini V, Barbara G, Granito A, De Ponti F, Corinaldesi R, Bianchi FB (2002) Clinical findings and anti-neuronal antibodies in coeliac disease with neurological disorders. Scand J Gastroenterol 37:1276–1281PubMedCrossRefGoogle Scholar
  63. Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, Beri R, Dolcino M, Valletta E, Corrocher R, Puccetti A (2006) In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 3:e358PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Paediatric Research CentreMedical School, University of Tampere and Tampere University HospitalTampereFinland
  2. 2.Medical School and Department of Gastroenterology and Alimentary Tract SurgeryUniversity of Tampere and Tampere University HospitalTampereFinland

Personalised recommendations